Drug Watch: Rare cancers (PDF) (March 2011)

News
Article

Agents in late-stage development for the treatment of rare cancers.

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!
Recent Videos
Related Content
freebird7977-stock@adobe.com

Novo Nordisk Teams with Form Health, 9amHealth for Obesity Care

Denise Myshko
August 28th 2025
Article

Read More

olgakris-stock@adobe.com

Lilly’s Oral GLP-1 Meets Endpoints in Phase 3 Trial

Denise Myshko
August 28th 2025
Article

Read More

Ellen Kelsay-stock@adobe.com

Employers: Cancer, GLP-1 Drugs and Mental Health Driving Healthcare Costs

Denise Myshko
August 28th 2025
Article

Read More

FDA Approves First in Class Therapy for Hereditary Angioedema

FDA Approves First in Class Therapy for Hereditary Angioedema

Denise Myshko
August 28th 2025
Article

Read More

MedImpact To Offer Unbranded Ustekinumab-aekn Biosimilar

MedImpact To Offer Unbranded Ustekinumab-aekn Biosimilar

Logan Lutton
August 28th 2025
Article

Read More

ryanking999-stock.adobe.com

FDA Set Review Date for Imcivree for Rare Form of Obesity

Denise Myshko
August 28th 2025
Article

Read More

© 2025 MJH Life Sciences

All rights reserved.